Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.

@article{Yoon2017AdjunctiveBA,
  title={Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.},
  author={Seoyoung Yoon and Sang Won Jeon and Young-Hoon Ko and Ashwin A. Patkar and Prakash S. Masand and Chi-Un Pae and Changsu Han},
  journal={Journal of clinical psychopharmacology},
  year={2017},
  volume={37 1},
  pages={
          46-53
        }
}
PURPOSE/BACKGROUND Brexpiprazole was approved for adjunctive treatment of major depressive disorder (MDD) in 2015. Because only a small number of randomized controlled trials have investigated the use of brexpiprazole in MDD, we performed a meta-analysis. METHODS/PROCEDURES We systematically searched literatures in PubMed, Cochrane Library database, EMBASE, Google Scholar, and clinicaltrials.gov up to January 2016. The primary efficacy measure was the mean change in total Montgomery-Åsberg… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 58 REFERENCES

The metabolic tolerability profile of adjunct brexpiprazole (opc-34712) in major depressive disorder American Society of Clinical Psychopharmacology

JC Nelson, A Skuban, M Hobart
  • June 22–25,
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Brexpiprazole: so far so good.

  • Therapeutic advances in psychopharmacology
  • 2016
VIEW 1 EXCERPT

GRADEpro Guideline Development Tool [software] (developed by Evidence Prime, Inc)

GRADEpro GDT
  • Available at: gradepro.org. Accessed May
  • 2016
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…